Search Results - "Rousell, R H"

The pharmacology of a new pasteurized antihemophilic factor concentrate derived from human blood plasma by Rousell, R H, Kasper, C K, Schwartz, R S

“…The pharmacology of a new pasteurized factor VIII (FVIII) concentrate derived from human blood plasma was studied in 23 adults with hemophilia A. In Part 1 of…”
Get more information

Transmission of hepatitis after the administration of intravenous immunoglobulins by Rousell, R H, Dobkin, M B, Budinger, M D, Louie, R E

Get more information

Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases by Ochs, H D, Fischer, S H, Wedgwood, R J, Wara, D W, Cowan, M J, Ammann, A J, Saxon, A, Budinger, M D, Allred, R U, Rousell, R H

“…To assess safety and efficacy of high-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency syndromes we treated a group of 19…”
Get more information

A new intravenous immunoglobulin in adult and childhood idiopathic thrombocytopenic purpura: a review by Rousell, R H

“…This is a review of the work leading to the generalized use of intravenous immunoglobulins (IVIgG) in the treatment of idiopathic thrombocytopenic purpura…”
Get more information

Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25 by Rousell, R H, Budinger, M D, Pirofsky, B, Schiff, R I

“…Recent reports of transmission by intravenous gamma-globulin preparations of non-A non-B hepatitis (NANBH), including several cases that progressed to severe…”
Get more information

Anticomplementary activity and the safety of intravenous immunoglobulin by Rousell, R H, Budinger, M D, Keppler, D C, Victor, R, Minaga, T

“…Quality assurance release levels for anti-complementary (AC) activity of a non-modified intravenous immunoglobulin (IGIV, pH 4.25) were reviewed over a period…”
Get more information

Immune globulin for intravenous infusion by Rousell, R H

Get more information

Crohn's Disease by Rousell, R. H.

Get full text

Antibody levels in reduced/alkylated intravenous immune globulin by Rousell, R H, Collins, M S, Dobkin, M B, Louie, R E, Roby, R E, Sweet, B H

“…Antibody titers, found in representative lots of a reduced and alkylated intravenous immune globulin, against a variety of common microorganisms are presented…”
Get more information

Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin

Get full text

Heat treatment of factor VIII concentrate by Rousell, R H

Get more information

Clinical safety of intravenous immune globulin and freedom from transmission of viral disease by Rousell, R H

“…Although rare, side-effects have been associated with the administration of iv immune globulins (IVIG). While the clinical presentation may be similar, several…”
Get more information

Points from Letters: Prophylaxis of Venous Thrombosis by Rousell, R. H.

Get full text

Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication by Rousell, R H, Good, R A, Pirofsky, B, Schiff, R I

“…Evidence for transmission of non-A non-B hepatitis (NANB) was sought in 41 patients with primary immune deficiency who were receiving human intravenous immune…”
Get more information

Reactions to Haemaccel by Bogie, W, Rousell, R H

Get more information

Units for immunoreactive trypsin by Wood, T P, Redshaw, M R, Rousell, R H

Get more information

Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom by Aber, C P, Bass, N M, Berry, C L, Carson, P H, Dobbs, R J, Fox, K M, Hamblin, J J, Haydu, S P, Howitt, G, MacIver, J E, Portal, R W, Raftery, E B, Rousell, R H, Stock, J P

“…In a multicentre trial of streptokinase in acute myocardial infarction 302 patients received an intravenous infusion of 2 500 000 IU of streptokinase over 24…”
Get full text

A summary of the world-wide clinical investigations of recombinant factor VIII by Schwartz, R S, Rousell, R H

Get more information

Safety and patient acceptability of intravenous immune globulin in 10% maltose by Ochs, H D, Buckley, R H, Pirofsky, B, Fischer, S H, Rousell, R H, Anderson, C J, Wedgwood, R J

“…The safety and patient acceptance of two preparations of modified (reduced and alkylated) immune globulin for intravenous use were evaluated; one preparation…”
Get more information

Elimination of human immunodeficiency virus from immunoglobulin preparations

Get more information